Fennec Pharmaceuticals Inc (FENC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Fennec Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 9.60 $ — 70% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 63.2% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.30 | 0.18 – 0.47 | 70 | 204.7% | 5 |
| 12/31/2027 | 0.89 | 0.55 – 1.47 | 100 | 200.7% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.06 | – | 8 | -18.60 | -25.00 | -2 | -2 |
| 2025: Q1 | -0.03 | -109.10 | 9 | -65.50 | -13.30 | -4 | -4 |
| 2025: Q2 | -0.09 | – | 10 | 32.90 | -32.70 | -4 | -4 |
| 2025: Q3 | -0.02 | – | 13 | 78.70 | -5.10 | 2 | 2 |
| 2025: Q4 | -0.14 | – | 14 | 73.80 | -34.70 | -6 | -6 |
| 2026: Q1 | 0.01 | – | 15 | 72.60 | 1.30 | 2 | 2 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -3 | -3 | -0.22 | -2 | 4 | 4 |
| 2017 | 0 | -7 | -7 | -0.47 | -4 | 27 | 28 |
| 2018 | 0 | -10 | -10 | -0.52 | -8 | 21 | 23 |
| 2019 | 0 | -13 | -12 | -0.63 | -9 | 12 | 14 |
| 2020 | 0 | -18 | -18 | -0.76 | -16 | 29 | 31 |
| 2021 | 0 | -17 | -17 | -0.67 | -14 | 16 | 22 |
| 2022 | 2 | -23 | -24 | -0.90 | -18 | -3 | 27 |
| 2023 | 21 | -13 | -16 | -0.60 | -17 | -12 | 27 |
| 2024 | 48 | 2 | 0 | -0.02 | 27 | -6 | 45 |
| 2025 | 45 | -6 | -10 | -0.34 | -12 | 35 | 70 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Fennec Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen in der Vermarktungsphase in den USA.
| Employees | 35 |
|---|---|
| Headquarters | Research Triangle Park, NC |
| Address | 68 TW Alexander Drive, 27709 Research Triangle Park, United States |
| Phone | 919 636 4530 |
| Website | fennecpharma.com |
| IPO Date | 5. Jun 2001 |
| ISIN | CA31447P1009 |
| Stock Split | 1:3 on 09/09/2014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey S. Hackman | CEO & Director | 1963 |
| Robert C. Andrade | Chief Financial Officer | 1975 |
| Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer | – |
| Terry Evans | Chief Commercial Officer | – |
| Christiana Cioffi M.B.A. | Chief Strategy Officer | – |
| Mark Gowland | Controller | – |
| Lei Fang | President of Pharstat Inc | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.